This is a StreetInsider.com Premium Only Page

Aprea Therapeutics (APRE) – Management Comments

Jun 16, 2021 08:00 AM Aprea Therapeutics (APRE) Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint

Oct 7, 2020 08:04 AM Aprea Therapeutics (APRE) Reports FDA Acceptance of IND to Begin Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548

Sep 29, 2020 08:11 AM

Jul 16, 2020 07:02 AM

Jun 12, 2020 06:05 AM

Jun 3, 2020 08:06 AM

Jan 30, 2020 07:38 AM

Dec 12, 2019 08:33 AM